Actualités de Lucerne

Kunstmuseum St.Gallen

2

Installation with Pop-up Café at the Kunstmuseum St.Gallen | Thi My Lien Nguyen: Shaping Fluidity

Carl F. Bucherer

8

Press release: The Heritage Chronometer Celebration by CFB

Gletschergarten Luzern

The new Felsenwelt in the Glacier Garden is a journey through time

Carl F. Bucherer

SAVE THE DATE: Carl F. Bucherer at Watches and Wonders 2021

MSD Merck Sharp & Dohme AG

MSD (Merck Sharp & Dohme AG) Switzerland appoints Ans Heirman, Ph.D. as the new Managing Director of MSD Switzerland, effective September 1st, 2020

swissstaffing - Verband der Personaldienstleister der Schweiz

Flexworkers are the subject of a new study

MSD Merck Sharp & Dohme AG

MSD in Switzerland launches new gender-neutral parental leave policy effective February 1st, 2020

Lucerne (ots) - Following its nomination for an eight time in a row as Top Employer Switzerland, MSD (Merck Sharp & Dohme AG) is delighted to announce the introduction of a new gender-neutral parental leave policy to all its employees within ...

MSD Merck Sharp & Dohme AG

On World Cancer Day, MSD Switzerland Stands United in Support of its Patients

Lucerne (ots) - World Cancer Day every 4th of February is a global uniting movement led by the Union for International Cancer Control (UICC). MSD (Merck Sharp & Dohme) is a proud sponsor of this initiative, joining the conversation to create a groundswell of awareness and action that will enable powerful ...

MSD Merck Sharp & Dohme AG

MSD Expands Operations in Switzerland

Lucerne (ots) - - Company will open a new location in Zurich, focused on accelerating research, data and commercialization of our medicines and vaccines - Lucerne will remain the center of MSD's presence in Switzerland MSD (Merck Sharp & Dohme AG) today announced that it will establish a new office in Zurich, Switzerland, aimed at accelerating the ...

MSD Merck Sharp & Dohme AG

Swissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)

Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...

Hochschule Luzern

Swiss crowdfunding volume exceeds half a billion Swiss francs for the first time